Fig 1C and 1D shows serum levels of TFPI2 and CA125 in patient populations stratified as follows: benign ovarian tumors were divided into EMS and non-EMS; EOCs were divided according to histological subtype; and uterine tumors were divided into uterine fibroids, cervical cancer, and endometrial cancer. Here, TFPI2 is linked to ovarian benign neoplasm.